C-terminal trans,trans-muconic acid ethyl ester partial retro-inverso pseudopeptides as proteasome inhibitors

References

• Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 2006;145:676–684.
   PubMed Web of Science ®Google Scholar
• McGrath JP, Jentsch S, Varshavsky A. UBA 1: an essential yeast gene encoding ubiquitin-activating enzyme. EMBO J 1991;10:227–236.
   PubMed Web of Science ®Google Scholar
• Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386:463–471.
   PubMed Web of Science ®Google Scholar
• Groll M, Bajorek M, Köhler A, Moroder L, Rubin DM, Huber R et al. A gated channel into the proteasome core particle. Nat Struct Biol 2000;7:1062–1067.
   PubMedGoogle Scholar
• Navon A, Goldberg AL. Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. Mol Cell 2001;8:1339–1349.
   PubMed Web of Science ®Google Scholar
• Groll M, Heinemeyer W, Jäger S, Ullrich T, Bochtler M, Wolf DH et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci USA 1999;96:10976–10983.
   PubMed Web of Science ®Google Scholar
• Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007;107:687–717.
   PubMed Web of Science ®Google Scholar
• Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007;35:12–17.
   PubMed Web of Science ®Google Scholar
• Britton M, Lucas MM, Downey SL, Screen M, Pletnev AA, Verdoes M et al. Selective inhibitor of proteasome’s caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol 2009;16:1278–1289.
   PubMed Web of Science ®Google Scholar
• Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739–758.
   PubMed Web of Science ®Google Scholar
• Hines J, Groll M, Fahnestock M, Crews CM. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem Biol 2008;15:501–512.
   PubMed Web of Science ®Google Scholar
• Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417–421.
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383–6391.
   PubMed Web of Science ®Google Scholar
• Nazif T, Bogyo M. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc Natl Acad Sci USA 2001;98:2967–2972.
   PubMed Web of Science ®Google Scholar
• Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995;268:726–731.
   PubMed Web of Science ®Google Scholar
• Groll M, Huber R, Potts BC. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 2006;128:5136–5141.
   PubMed Web of Science ®Google Scholar
• Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, Powell TK et al. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 2008;452:755–758.
   PubMed Web of Science ®Google Scholar
• Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 2012;19:99–115.
   PubMed Web of Science ®Google Scholar
• Groll M, Huber R, Moroder L. The persisting challenge of selective and specific proteasome inhibition. J Pept Sci 2009;15:58–66.
   PubMed Web of Science ®Google Scholar
• Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Curr Top Med Chem 2010;10:232–256.
   PubMed Web of Science ®Google Scholar
• Kohno J, Koguchi Y, Nishio M, Nakao K, Kuroda M, Shimizu R et al. Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093. J Org Chem 2000;65:990–995.
   PubMed Web of Science ®Google Scholar
• Marastoni M, Baldisserotto A, Canella A, Gavioli R, Risi CD, Pollini GP et al. Arecoline tripeptide inhibitors of proteasome. J Med Chem 2004;47:1587–1590.
   PubMed Web of Science ®Google Scholar
• Marastoni M, Baldisserotto A, Trapella C, Gavioli R, Tomatis R. P3 and P4 position analysis of vinyl ester pseudopeptide proteasome inhibitors. Bioorg Med Chem Lett 2006;16:3125–3130.
   PubMed Web of Science ®Google Scholar
• Baldisserotto A, Ferretti V, Destro F, Franceschini C, Marastoni M, Gavioli R et al. Alpha,beta-unsaturated N-acylpyrrole peptidyl derivatives: new proteasome inhibitors. J Med Chem 2010;53:6511–6515.
   PubMed Web of Science ®Google Scholar
• Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today 2010;15:40–56.
   PubMed Web of Science ®Google Scholar
• Chorev M. The partial retro-inverso modification: a road traveled together. Biopolymers 2005;80:67–84.
   PubMedGoogle Scholar
• Pallai P, Goodman M. Preparation of optically pure monoacyl 2-alkyl gem-diamines from peptide amides. J Chem: Soc Chem Commun 1982;5:280–281.
   Google Scholar
• Gavioli R, Vertuani S, Masucci MG. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors. Int J Cancer 2002;101:532–538.
   PubMed Web of Science ®Google Scholar
• Marastoni M, Baldisserotto A, Cellini S, Gavioli R, Tomatis R. Peptidyl vinyl ester derivatives: new class of selective inhibitors of proteasome trypsin-like activity. J Med Chem 2005;48:5038–5042.
   PubMedGoogle Scholar
• Lei B, Abdul Hameed MD, Hamza A, Wehenkel M, Muzyka JL, Yao XJ et al. Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations. J Phys Chem B 2010;114:12333–12339.
   PubMedGoogle Scholar